Hims & Hers Health (HIMS) has emerged as a disruptive force in telehealth, leveraging technology and personalization to address highly-personal health conditions while achieving scalable profitability ...

Hims & Hers Health stock is trading -39.24% below its average target price of $44.82 after marking a 1.0% during today's ...

Hims & Hers Health, Inc. (HIMS) ended the recent trading session at $27.23, demonstrating a +1.04% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.13% gain on the ...

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

BofA Securities reiterated its Underperform rating on Hims & Hers Health (NYSE:HIMS), keeping its price target steady at $22, ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Veterinary telehealth company Dutch is highlighting an overall lack of vet care options for pet owners nationwide.

Philippine healthcare companies secured a combined $79 million in actual and potential sales at the HIMSS Global Health ...